Eiger, Daniel http://orcid.org/0000-0002-9879-6048
Franzoi, Maria Alice
Pondé, Noam
Brandão, Mariana
de Angelis, Claudia
Schmitt Nogueira, Melanie
de Hemptinne, Quentin
de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Clinical trials referenced in this document:
Documents that mention this clinical trial
Neoadjuvant HER2-targeted therapy ± immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps634
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
https://doi.org/10.1136/esmoopen-2019-000659
Documents that mention this clinical trial
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer
https://doi.org/10.1136/esmoopen-2020-000688
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
https://doi.org/10.1136/esmoopen-2019-000659
This article is maintained by: Elsevier
Article Title: Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
Journal Title: ESMO Open
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/esmoopen-2019-000659
Content Type: article
Copyright: © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.